BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Cidara Therapeutics Stock Surges on FDA Breakthrough Therapy Designation for Flu Drug
Cidara Therapeutics Stock Surges on FDA Breakthrough Therapy Designation for Flu Drug
11
3
BTCCSquare news:
Cidara Therapeutics saw its stock price jump over 12% following the FDA's Breakthrough Therapy designation for its investigational flu drug CD388. The regulatory nod accelerates the approval process for this non-vaccine prophylactic treatment targeting seasonal influenza.
The drug, already in Phase 3 trials, represents a potential breakthrough for patients unable or unwilling to receive traditional vaccines. CEO Jeffrey Stein emphasized the significance of this development, noting CD388's potential to address unmet medical needs in influenza prevention.
By:
